[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SG11202001368SA - Antigen-binding proteins tatrgeting shared antigens - Google Patents

Antigen-binding proteins tatrgeting shared antigens

Info

Publication number
SG11202001368SA
SG11202001368SA SG11202001368SA SG11202001368SA SG11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA SG 11202001368S A SG11202001368S A SG 11202001368SA
Authority
SG
Singapore
Prior art keywords
tatrgeting
antigen
binding proteins
shared antigens
antigens
Prior art date
Application number
SG11202001368SA
Inventor
Karin Jooss
Wade Blair
Brendan Bulik-Sullivan
Jennifer Busby
Michele Anne Busby
Mojca Skoberne
Roman Yelensky
Joshua Francis
Gijsbert Grotenbreg
Original Assignee
Gritstone Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gritstone Oncology Inc filed Critical Gritstone Oncology Inc
Publication of SG11202001368SA publication Critical patent/SG11202001368SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A61K39/001191—Melan-A/MART
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202001368SA 2017-08-18 2018-08-17 Antigen-binding proteins tatrgeting shared antigens SG11202001368SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762547146P 2017-08-18 2017-08-18
US201762581368P 2017-11-03 2017-11-03
PCT/US2018/046997 WO2019036688A1 (en) 2017-08-18 2018-08-17 Antigen-binding proteins tatrgeting shared antigens

Publications (1)

Publication Number Publication Date
SG11202001368SA true SG11202001368SA (en) 2020-03-30

Family

ID=65362959

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202001368SA SG11202001368SA (en) 2017-08-18 2018-08-17 Antigen-binding proteins tatrgeting shared antigens

Country Status (12)

Country Link
US (2) US20210147550A1 (en)
EP (1) EP3668539A4 (en)
JP (1) JP2021500852A (en)
KR (1) KR20200084320A (en)
CN (1) CN111328288A (en)
AU (1) AU2018318303A1 (en)
CA (1) CA3072816A1 (en)
IL (1) IL272466A (en)
MX (1) MX2020001879A (en)
SG (1) SG11202001368SA (en)
WO (1) WO2019036688A1 (en)
ZA (1) ZA202001285B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62575B1 (en) 2014-12-23 2021-12-31 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
US9422547B1 (en) 2015-06-09 2016-08-23 Gigagen, Inc. Recombinant fusion proteins and libraries from immune cell repertoires
EP3630163A4 (en) 2017-05-24 2021-06-09 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
WO2019133853A1 (en) * 2017-12-28 2019-07-04 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared antigens
EP3784255A4 (en) * 2018-04-19 2022-06-22 Board of Regents, The University of Texas System T cell receptors with mage-b2 specificity and uses thereof
CN111138521B (en) * 2018-11-06 2022-10-28 香雪生命科学技术（广东）有限公司 Short peptides derived from AFP antigen
CN111138522B (en) * 2018-11-06 2023-01-24 香雪生命科学技术（广东）有限公司 Tumor antigen short peptides derived from AFP
WO2020191365A1 (en) * 2019-03-21 2020-09-24 Gigamune, Inc. Engineered cells expressing anti-viral t cell receptors and methods of use thereof
EP3714941A1 (en) * 2019-03-27 2020-09-30 Medigene Immunotherapies GmbH Mage-a4 tcrs
US20200318068A1 (en) * 2019-04-04 2020-10-08 Immatics US, Inc. Use of retinoic acid in t-cell manufacturing
US20220213167A1 (en) * 2019-05-03 2022-07-07 Gigamune, Inc. Engineered cells expressing anti-tumor t cell receptors and methods of use thereof
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
EP3997116A1 (en) * 2019-07-09 2022-05-18 Medigene Immunotherapies GmbH Magea10 specific t cell receptors and their use
KR20220047277A (en) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 HIV Vaccines, and Methods of Making and Using the Same
CN112300261B (en) * 2019-07-23 2023-03-17 香雪生命科学技术（广东）有限公司 Tumor antigen short peptide derived from AFP
AU2020333757A1 (en) * 2019-08-19 2022-03-24 Pandion Operations, Inc. Targeted immunotolerance with a PD-1 agonist
WO2021048381A1 (en) * 2019-09-13 2021-03-18 Evaxion Biotech Aps Method for identifying stable mhc binding peptides using mass spectrometry
WO2021076939A1 (en) * 2019-10-18 2021-04-22 Board Of Regents, The University Of Texas System Hla-restricted vcx/y peptides and t cell receptors and use thereof
WO2021092094A1 (en) * 2019-11-04 2021-05-14 Gritstone Oncology, Inc. Antigen-binding proteins targeting shared neoantigens
KR20220098379A (en) * 2019-11-15 2022-07-12 그릿스톤 바이오, 인코포레이티드 Antigen-binding protein targeting covalent neoantigens
CN112898399A (en) * 2019-12-03 2021-06-04 香雪生命科学技术（广东）有限公司 Short peptides derived from AFP antigens
CN115960207A (en) * 2019-12-13 2023-04-14 南京大户生物科技有限公司 Thymus-dependent lymphocyte antigen epitope peptide of primary liver cancer-related antigen and application thereof
CN113072636B (en) * 2020-01-06 2024-05-28 香雪生命科学技术（广东）有限公司 T cell receptor for identifying AFP and coding sequence thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
CN113321727B (en) * 2020-02-28 2024-04-09 香雪生命科学技术（广东）有限公司 T cell receptor for identifying AFP antigen short peptide and coding sequence thereof
CN113321725B (en) * 2020-02-28 2024-06-11 香雪生命科学技术（广东）有限公司 T cell receptor for identifying AFP
KR20220167276A (en) * 2020-03-10 2022-12-20 매사추세츠 인스티튜트 오브 테크놀로지 Compositions and methods for immunotherapy of NPM1c-positive cancers
CN113493505A (en) * 2020-03-20 2021-10-12 香雪生命科学技术（广东）有限公司 High affinity TCR recognizing AFP antigen
US20220017636A1 (en) * 2020-05-19 2022-01-20 Amgen Inc. Mageb2 binding constructs
CN116096740A (en) * 2020-06-09 2023-05-09 得克萨斯州大学系统董事会 Engineered T cell receptors and methods of use
JP7391208B2 (en) 2020-07-08 2023-12-04 エルジー エナジー ソリューション リミテッド Battery packs and automobiles containing them
EP4188962A1 (en) * 2020-07-29 2023-06-07 Gritstone bio, Inc. Engineered multi-specific antibodies and related methods of use and manufacture
JP2023540123A (en) * 2020-09-04 2023-09-21 アメリカ合衆国 T cell receptor that recognizes R273C or Y220C mutation in P53
CA3194664A1 (en) * 2020-10-23 2022-04-28 Xi Chen Compositions and methods for t-cell receptor identification
WO2022098845A1 (en) * 2020-11-05 2022-05-12 Board Of Regents, The University Of Texas System Engineered t cell receptors targeting egfr antigens and methods of use
WO2022155503A1 (en) * 2021-01-14 2022-07-21 Gritstone Bio, Inc. Multi-specific antibodies and methods of use
CR20230312A (en) 2021-01-14 2023-08-31 Gilead Sciences Inc Hiv vaccines and methods of using
EP4294831A1 (en) * 2021-02-16 2023-12-27 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against cd22
CA3210289A1 (en) 2021-03-09 2022-09-15 Anna Maria SOBIERAJ Mage-a4 peptide-mhc antigen binding proteins
US20240293459A1 (en) * 2021-03-29 2024-09-05 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting sars-cov-2 antigens and methods of use
EP4329780A1 (en) 2021-04-29 2024-03-06 Yeda Research and Development Co. Ltd T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same
EP4091627A1 (en) * 2021-05-21 2022-11-23 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Tcr constructs specific for magea4-derived epitopes
KR20240045239A (en) * 2021-08-06 2024-04-05 안야디, 엘엘씨 Manufacturing method of personalized cancer immunotherapy
WO2023050063A1 (en) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 Tcr recognizing hla-a*02:01/e629-38, and application thereof
EP4423143A1 (en) * 2021-10-29 2024-09-04 Yafei Hou T cell receptor recognizing r175h mutation in p53 and its application
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
WO2023164455A2 (en) * 2022-02-23 2023-08-31 Aloe Therapeutics Inc Compositions and methods to modulate the immune system
NL2031118B1 (en) * 2022-03-01 2023-09-07 Academisch Ziekenhuis Leiden T cell receptors directed against transcription factor wt1 and uses thereof
CN116836261A (en) * 2022-03-24 2023-10-03 香雪生命科学技术（广东）有限公司 High-affinity TCR (TCR) for recognizing MAGE-A4 antigen, and sequence and application thereof
TW202430545A (en) * 2022-10-05 2024-08-01 美商帝斯肯醫療公司 Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
CN116158405B (en) * 2023-01-30 2024-04-26 西北农林科技大学 Method for improving offspring lamb rate of milk goats

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
CA2476625A1 (en) * 2002-02-20 2003-08-28 Dyax Corp. Mhc-peptide complex binding ligands
US9221902B2 (en) * 2008-11-07 2015-12-29 Fabrus, Inc. Combinatorial antibody libraries and uses thereof
PL3392270T3 (en) * 2011-09-15 2021-03-08 The United States Of America, As Represented By The Secretary Department Of Health And Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
US20150018530A1 (en) * 2012-02-29 2015-01-15 Ambrx, Inc. Novel Prodrug Containing Molecule Compositions and Their Uses
TWI702229B (en) * 2014-12-19 2020-08-21 美商再生元醫藥公司 Human antibodies to influenza hemagglutinin
CN107921127B (en) * 2015-05-22 2022-04-08 纪念斯隆-凯特琳癌症中心 T cell receptor-like antibodies specific for PRAME peptides
GB201520559D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017124001A2 (en) * 2016-01-14 2017-07-20 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for foxp3-derived peptides

Also Published As

Publication number Publication date
US20230382997A1 (en) 2023-11-30
JP2021500852A (en) 2021-01-14
WO2019036688A1 (en) 2019-02-21
KR20200084320A (en) 2020-07-10
CN111328288A (en) 2020-06-23
EP3668539A1 (en) 2020-06-24
CA3072816A1 (en) 2019-02-21
AU2018318303A1 (en) 2020-04-09
ZA202001285B (en) 2021-08-25
US20210147550A1 (en) 2021-05-20
IL272466A (en) 2020-03-31
MX2020001879A (en) 2020-07-29
EP3668539A4 (en) 2021-08-18

Similar Documents

Publication Publication Date Title
SG11202001368SA (en) Antigen-binding proteins tatrgeting shared antigens
IL275547A (en) Antigen-binding proteins targeting shared antigens
IL279321A (en) Anti-sirpα antibody
ZA201900353B (en) Anti-pd-l1 antibodies
IL280780A (en) Anti-tigit antibodies
IL262295B1 (en) Anti-pd-l1 antibodies
IL267797B1 (en) Anti-gpc3 antibody
IL280013A (en) Anti-il36r antibodies
IL279352A (en) Il-11ra antibodies
SG10201603721TA (en) Anti-CTLA-4 Antibodies
IL278010A (en) Galectin-10 antibodies
IL262776A (en) Humanized anti-il-1r3 antibodies
IL277030A (en) Antibodies
GB202110263D0 (en) Anti-btla antibodies
ZA202101177B (en) Anti-btla antibody
GB201811368D0 (en) Antibody
GB201817172D0 (en) Antibody
IL273529A (en) Anti-pacap antibody
GB201806084D0 (en) Antibodies
GB201511196D0 (en) Monoclonal antibodies
GB201819952D0 (en) Antibodies
GB201817311D0 (en) Antibodies
GB201817312D0 (en) Antibodies
GB201817313D0 (en) Antibodies
GB201817309D0 (en) Antibodies